CENTER FOR IMMUNIZATION RESEARCH

MILESTONES



First human trials of a preventive human papillomavirus cervical cancer vaccine (HPV 16). This virus-like particle (VLP) vaccine was the progenitor of the HPV vaccine (Gardasil) recently licensed by the FDA, & of a second vaccine (Cervarix).

• 1997-2001

• 1998-2003

1998-2003 •····

1998-2003 •---

1999-2003 •

VaxGen, Inc. Lead clinical trial site in first phase III HIV vaccine trial.

NIH/NIAID

Lead clinical trial site for first human studies of live attenuated recombinant RSV vaccines.

Avant/Microscience

Leading single dose, oral cholera (Peru-15) & typhoid vaccines (MICRO-TY/ZH9) shown to be safe & immunogenic in early Phase I/II trials performed in Baltimore & Vermont (typhoid only).

SBL Vaccines

Established efficacy of whole cell ETEC vaccine in field trials in Guatemala & Mexico.

• 1998-2002

Salix

Multicenter clinical trials that led to licensure of Rifamixin for treatment of traveler's diarrhea.

NIH/NIAID First human trial of a recombinant dengue virus vaccine; additional trials are ongoing. 6

• 1999-2006

2000-2002 •

Intellivax

First human trial of intranasal Shigella vaccine demonstrated short-term protection against Shigella flexneri in an experimental challenge model.

NIH/DAIDS/HVTN & AlphaVax, Inc.

Lead clinical trial site for 1st human study of HIV vaccine using Venezuelan Equine Encephalitis vector.

2000-2005

2000-2005

Acambis/IOMAI

Challenge studies evaluating ETEC vaccines demonstrated that anti-CS3 serum IgA titer is a marker for protection against strains sharing this colonization factor.

Merck & Co.

Lead site for the first human testing of a live-attenuated adenovirus vectored HIV vaccine.

• 2001-2006


NIH/NIAID

First human trial of malaria transmission blocking vaccine.

2002 •

CENTER FOR IMMUNIZATION RESEARCH

MILESTONES



2006-2007 •

IOMAI

Phase II field study finds an ETEC vaccine delivered transcutaneously by arm patch protects travelers to Guatemala and Mexico.

PATH/EVI

Developed and validated low-inoculum ETEC challenge model in human volunteers that enabled 2 log reduction in challenge strain while maintainging consistently high attack rates.

• 2009

CSL Limited

2009 •

Principal Investigators and lead site in a large multicenter trial of a pandemic H1N1 influenza vaccine.

Norovirus Vaccine Against Experimental Human Norwalk Virus Illness

This norovirus VLP vaccine provides protection against illness and infection after challenge with a homologous virus.


• 2011

2012 •-----

ACIP Appointment

Dr. Ruth Karron was appointed to the Advisory Committee on Immunization Practices. CENTER FOR IMMUNIZATION RESEARCH

MILESTONES



MILESTONE NO. 12

Lorem ipsum Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam.